Skip to content
Screener

Mineralys Therapeutics, Inc. MLYS Total Current Liabilities

Total Current Liabilities at other companies

Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
$14.71M-57.8%
Mannkind logo
MannkindMNKD
$142.9M+27.8%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$17.77M+0.9%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$71.09M+24.0%
Tenet Healthcare logo
Tenet HealthcareTHC
$5.57B+30.3%
Medtronic logo
MedtronicMDT
$11.66B-9.5%

Other financials

Income statement

See full
Operating income-$45.3M-2.0%
Net income-$39.3M+6.8%
EPS (diluted)-$0.47+40.5%

Balance sheet

See full
Cash & equivalents$1.2M-14.6%
Total equity$638.1M+86.8%
Total assets$652.9M+83.9%

Cash flow

See full
Operating cash flow-$39.5M+13.2%
CapEx$15.0K
Free cash flow-$37.9M+43.3%

Valuation

See full
Market cap$2.38B+171%

Returns & leverage

See full
Return on equity-31%-9.6pp
Current ratio44.3×+17.8×

Where this comes from

Reported directly by Mineralys Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The source filing: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 5:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001933414-26-000084
Line itemMarch 31, 2026December 31, 2025
Current liabilities:
Accounts payable$1,116$2,017
Accrued liabilities13,60213,096
Total current liabilities14,71815,113
Commitments and contingencies (Note 4)
Stockholders’ equity:
Common stock, $0.0001 par value; 500,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 82,454,950 and 81,536,557 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively88
Additional paid-in capital1,134,6441,103,854

Item 1. Financial Statements

FAQ

What is Mineralys Therapeutics, Inc.'s total current liabilities?
Mineralys Therapeutics, Inc. (MLYS) reported total current liabilities of $14.72M in Q1 2026.
How has Mineralys Therapeutics, Inc.'s total current liabilities changed year-over-year?
Mineralys Therapeutics, Inc.'s total current liabilities increased by 10.0% year-over-year, from $13.39M to $14.72M.
What is the long-term trend for Mineralys Therapeutics, Inc.'s total current liabilities?
Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s total current liabilities has grown at a 23.3% compound annual growth rate (CAGR), from $8.07M to $15.11M.
What does total current liabilities mean?
The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.

Ask your AI about Mineralys Therapeutics, Inc.'s total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude